Merck & Co. has agreed with Thermo Fisher Scientific to produce molnupiravir, Merck's oral drug for CVOD-19. The drug will be shipped from Thermo Fisher's Ontario site to Canada and the United Kingdom, as well as markets in the European Union, Asia-Pacific and Latin America. Previously, the Canadian government ordered 500,000 courses of molnupiravir with delivery in 2022 and the possibility of doubling the order.